These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
443 related articles for article (PubMed ID: 18479179)
1. Current and future antiretroviral treatment options in paediatric HIV infection. Giaquinto C; Morelli E; Fregonese F; Rampon O; Penazzato M; de Rossi A; D'Elia R Clin Drug Investig; 2008; 28(6):375-97. PubMed ID: 18479179 [TBL] [Abstract][Full Text] [Related]
2. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. ; Babiker A; Castro nee Green H; Compagnucci A; Fiscus S; Giaquinto C; Gibb DM; Harper L; Harrison L; Hughes M; McKinney R; Melvin A; Mofenson L; Saidi Y; Smith ME; Tudor-Williams G; Walker AS Lancet Infect Dis; 2011 Apr; 11(4):273-83. PubMed ID: 21288774 [TBL] [Abstract][Full Text] [Related]
3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
4. Nucleoside and nucleotide reverse transcriptase inhibitors in children. Giaquinto C; Rampon O; Penazzato M; Fregonese F; De Rossi A; D'Elia R Clin Drug Investig; 2007; 27(8):509-31. PubMed ID: 17638393 [TBL] [Abstract][Full Text] [Related]
5. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261 [TBL] [Abstract][Full Text] [Related]
6. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors. Bunupuradah T; Suntarattiwong P; Li A; Sirivichayakul S; Pancharoen C; Boonrak P; Puthanakit T; Kerr SJ; Ruxrungtham K; Chotpitayasunondh T; Hirschel B; Ananworanich J; Int J Infect Dis; 2010 Apr; 14(4):e311-6. PubMed ID: 19699673 [TBL] [Abstract][Full Text] [Related]
7. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration. Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008 [TBL] [Abstract][Full Text] [Related]
8. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Aboud M; Kaplan R; Lombaard J; Zhang F; Hidalgo JA; Mamedova E; Losso MH; Chetchotisakd P; Brites C; Sievers J; Brown D; Hopking J; Underwood M; Nascimento MC; Punekar Y; Gartland M; Smith K Lancet Infect Dis; 2019 Mar; 19(3):253-264. PubMed ID: 30732940 [TBL] [Abstract][Full Text] [Related]
9. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA; Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068 [TBL] [Abstract][Full Text] [Related]
10. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E; Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227 [TBL] [Abstract][Full Text] [Related]
11. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial. Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V; BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406 [TBL] [Abstract][Full Text] [Related]
13. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355 [TBL] [Abstract][Full Text] [Related]
14. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study. Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586 [TBL] [Abstract][Full Text] [Related]
15. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Sturt AS; Dokubo EK; Sint TT Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370 [TBL] [Abstract][Full Text] [Related]
16. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy. Humphreys EH; Chang LW; Harris J Cochrane Database Syst Rev; 2010 Jun; (6):CD006517. PubMed ID: 20556768 [TBL] [Abstract][Full Text] [Related]
17. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. ; Welch S; Sharland M; Lyall EG; Tudor-Williams G; Niehues T; Wintergerst U; Bunupuradah T; Hainaut M; Della Negra M; Pena MJ; Amador JT; Gattinara GC; Compagnucci A; Faye A; Giaquinto C; Gibb DM; Gandhi K; Forcat S; Buckberry K; Harper L; Königs C; Patel D; Bastiaans D HIV Med; 2009 Nov; 10(10):591-613. PubMed ID: 19878352 [TBL] [Abstract][Full Text] [Related]
18. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations. Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527 [TBL] [Abstract][Full Text] [Related]
19. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen. Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016 [TBL] [Abstract][Full Text] [Related]
20. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India. Gupta SB; Pujari SN; Joshi SR; Patel AK; J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]